A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)

• Status: Recruiting
• Trial end date: 2022-01-31

Summary

Primary Objectives:

To evaluate the safety (compared to iron sucrose) and efficacy of ferumoxytol in pediatric CKD subjects with iron deficiency anemia (IDA) or who are at risk of development of IDA

Secondary Objective:

To determine the single-dose pharmacokinetics (PK) and pharmacodynamics (PD) profile of ferumoxytol in pediatric subjects.

• Phase: Phase 3

Details

• Lead Sponsor: AMAG Pharmaceuticals, Inc.
• Treatments: Ferric Compounds; Ferric Oxide, Saccharated; Ferrosoferric Oxide; Iron